Market Overview

Celgene Says ABRAXANE Demonstrates Statistically Significant Improvement

Share:
Related CELG
These Companies Probably Won't Be Acquiring Ariad Pharmaceuticals
Phase II Data for Apremilast in Behçet's Disease Published in The New England Journal of Medicine
How To Invest In ETFs: Tips To Trade Top Market Trends (Investor's Business Daily)

Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that its phase III study of ABRAXANE^® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival. In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone.

Posted-In: News FDA

 

Related Articles (CELG)

Around the Web, We're Loving...